Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1 -Deficient Cells

29 Jan 2021

Abstract excerpt

Abstract Homologous recombination (HR)-deficient cancers are sensitive to poly-ADP ribose polymerase inhibitors (PARPi), which have shown clinical efficacy in the treatment of high-grade serous cancers (HGSC). However, the majority of patients will relapse, and acquired PARPi resistance is emerging as a pressing clinical problem. Here we generated seven single-cell clones with acquired PARPi resistance derived...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33514515
DOI: 10.1158/0008-5472.can-20-2912

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1 -Deficient CellsPMID 33514515Read ↗

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceSemantic proximity Read ↗

PARP Inhibitors Resistance: Mechanisms and PerspectivesSemantic proximity Read ↗

Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 ScreeningSemantic proximity Read ↗

Mechanism of PARP inhibitor resistance and potential overcoming strategiesSemantic proximity Read ↗

Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated CancerSemantic proximity Read ↗

Clinical approaches to overcome PARP inhibitor resistanceSemantic proximity Read ↗

PARP1 catalytic domain mutations drive high-level resistance to saruparib while preserving DNA damage response vulnerabilitiesSemantic proximity Read ↗

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitorsSemantic proximity Read ↗

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in <i>PARP1</i> causing PARP inhibitor resistanceSemantic proximity Read ↗

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity Read ↗

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistanceSemantic proximity Read ↗

‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.